Second-generation BCR-ABL kinase inhibitors in CML. 2010

Bengt Simonsson, and Kimmo Porkka, and Johan Richter

UI MeSH Term Description Entries
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068877 Imatinib Mesylate A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide,CGP 57148,CGP-57148,CGP57148B,Gleevec,Glivec,Imatinib,Imatinib Methanesulfonate,ST 1571,ST1571,STI 571,STI-571,STI571,CGP57148,Mesylate, Imatinib,Methanesulfonate, Imatinib
D000069439 Dasatinib A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB. (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide,BMS 354825,BMS-354825,BMS354825,N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide,Sprycel,354825, BMS
D001549 Benzamides BENZOIC ACID amides.
D013844 Thiazoles Heterocyclic compounds where the ring system is composed of three CARBON atoms, a SULFUR and NITROGEN atoms. Thiazole
D015466 Leukemia, Myeloid, Chronic-Phase The initial phase of chronic myeloid leukemia consisting of an relatively indolent period lasting from 4 to 7 years. Patients range from asymptomatic to those exhibiting ANEMIA; SPLENOMEGALY; and increased cell turnover. There are 5% or fewer blast cells in the blood and bone marrow in this phase. Granulocytic Leukemia, Chronic, Stable-Phase,Leukemia, Granulocytic, Chronic-Phase,Leukemia, Myelogenous, Chronic-Phase,Leukemia, Myeloid, Stable-Phase,Myelogenous Leukemia, Chronic, Chronic-Phase,Myeloid Leukemia, Chronic, Chronic-Phase,Myeloid Leukemia, Chronic, Stable-Phase,Granulocytic Leukemia, Chronic, Stable Phase,Leukemia, Granulocytic, Chronic Phase,Leukemia, Myelogenous, Chronic Phase,Leukemia, Myeloid, Chronic Phase,Leukemia, Myeloid, Stable Phase,Myelogenous Leukemia, Chronic, Chronic Phase,Myeloid Leukemia, Chronic, Chronic Phase
D016044 Fusion Proteins, bcr-abl Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC. Oncogene Protein p190(bcr-abl),Oncogene Protein p210(bcr-abl),bcr-abl Fusion Protein,bcr-abl Fusion Proteins,Bcr-Abl Tyrosine Kinase,Oncogene Protein p185(bcr-abl),Oncogene Protein p230(bcr-abl),p185(bcr-abl) Fusion Proteins,p190(bcr-abl) Fusion Proteins,p210(bcr-abl) Fusion Proteins,p230(bcr-abl) Fusion Proteins,Bcr Abl Tyrosine Kinase,Fusion Protein, bcr-abl,Fusion Proteins, bcr abl,Kinase, Bcr-Abl Tyrosine,Protein, bcr-abl Fusion,Tyrosine Kinase, Bcr-Abl,bcr abl Fusion Protein,bcr abl Fusion Proteins

Related Publications

Bengt Simonsson, and Kimmo Porkka, and Johan Richter
October 2010, The New England journal of medicine,
Bengt Simonsson, and Kimmo Porkka, and Johan Richter
October 2010, The New England journal of medicine,
Bengt Simonsson, and Kimmo Porkka, and Johan Richter
October 2010, The New England journal of medicine,
Bengt Simonsson, and Kimmo Porkka, and Johan Richter
May 2006, International journal of hematology,
Bengt Simonsson, and Kimmo Porkka, and Johan Richter
June 2020, International journal of molecular sciences,
Bengt Simonsson, and Kimmo Porkka, and Johan Richter
November 2006, Recent patents on anti-cancer drug discovery,
Bengt Simonsson, and Kimmo Porkka, and Johan Richter
September 2008, Expert review of anticancer therapy,
Bengt Simonsson, and Kimmo Porkka, and Johan Richter
August 2012, Clinical lymphoma, myeloma & leukemia,
Copied contents to your clipboard!